Recent advances in the development of selective small molecule inhibitors for Cyclin-dependent kinases

Current Topics in Medicinal Chemistry

Volumn 5, Issue 2, 2005, Pages 167-179

  Hirai, Hiroshi ^a   Kawanishi, Nobuhiko ^a   Iwasawa, Yoshikazu ^a,b  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CDK inhibitor; CDK2; CDK4; CDK6; Cyclin dependent kinase

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOTRIAZOLE; CARBAZOLE DERIVATIVE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 1 INHIBITOR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 4 INHIBITOR; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 6 INHIBITOR; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 8; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; GEMCITABINE; JNJ 7706621; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OXINDOLE; PD 0183812; PHA 533533; PROTEIN KINASE INHIBITOR; PUN 252808; PUN 292137; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CELL CYCLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CDC2-CDC28 KINASES; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HUMANS; PROTO-ONCOGENE PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 17144373673     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026053507688     Document Type: Review

References (104)

1. Sherr, C. J. Cancer cell cycles. Science 1996, 274, 1672-1677.
2. Sherr, C. J. The Pezcoller lecture: cancer cell cycles revised. Cancer Res. 2000, 60, 3689-3695.
3. Pines, J. Cyclins ands cyclin-dependent kinases: theme and variations. Adv. Cancer Res. 1995, 66, 181-212.
4. Sherr, C. J.; Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13, 1501-1512.
5. Pavletich, N. P. Mechanism of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and CIP and INK4 inhibitors. J. Mol. Biol. 1999, 287, 821-828.
6. Koepp, D. M.; Haper, J. W.; Elledge, S. J. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999, 97, 431-434.
7. Dyson, N. The regulation of E2F by pRb-family proteins. Genes Dev. 1998, 12, 2245-2262.
8. Zheng, L.; Lee, W. H. The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp. Cell Res. 2001, 264, 2-18.
9. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharm. Sci. 2002 23, 417-425.
10. Kobor, M. S.; Greenblatt, J. Regulation of transcription elongation by phosphorylation. Biochim. Biophys. Acta 2002, 1577, 261-275.
11. Oelgeschlager, T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J. Cell. Physiol. 2002, 190, 160-169.
12. Falco, G. D.; Giordan, A. CDK9 (PITALRE): a multifunctional cdc2-related kinase. J. Cell. Physiol. 1998, 177, 501-506.
13. Price, D. H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol. 2000, 20 2629-2634.
14. Dhavan, R.; Tsai, L-H. A decade of CDK5. Nat. Rev. Mol. Cell. Biol. 2001, 2, 749-759.
15. Lilja, L.; Yang, S.; Webb, D.; Juntti-Berggren, L.; Berggren, P., Bark, C. Cyclin-dependent kinase 5 promotes insulin exocytosis. J. Biol. Chem. 2001, 276, 34199-34205.
16. Hall, M.; Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancers. Adv. Cancer Res. 1996, 68, 67-108.
17. Fisher, P. M.; Gianella-Borradori, A. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs 2003, 12, 955-970.
18. Senderowicz, A. M.; Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 2000, 92, 376-387.
19. Sedlacek, H. H. Mechanism of action of flavopiridol. Crit. Rev. Oncol. Hematol. 2001, 38, 139-170.
20. Whittaker, S. R.; Walton, M. I.; Garrett, M. D., Workman, P. The cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine) inhibits Retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 2004, 64, 262-272.
21. Hamdouchi, C.; Keyser, H.; Collins, E.; Jaramillo,C.; De Diego, J-E.; Spencer, C. D.; Dempsey, J. A.; Anderson, B. D.; Leggett, T.; Stamm, N. B.; Schultz, R. M.; Watkins, S. A.; Cocke, K.; Lemke, S.; Burke, T. F.; Beckmann, R. P.; Dixon, J. T.; Gurganus, T. M., Rankl, N. B.; Houck, K. A.; Zhang, F.; Vieth, M.; Espinosa, J.; Timm, D. E.; Campbell, R. M.; Patel, B. K. R.; Brooks, H. B. The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines. Mol. Cancer Ther. 2004, 3 1-9.
22. Lane, M. E.; Yu, B.; Rice, A.; Lipson, K. E.; Liang, C.; Sun, L., Tang, C.; McMahon, G.; Pestell, R. G.; Wadler, S. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001, 61, 6170-6177.
23. Misra, R. N.; Xiao, H.; Kim, K. S.; Lu, S.; Han, W-C.; Barbosa, S. A.; Hunt, J. T.; Rawlins, D. B.; Shan, W.; Ahmed, S. Z.; Qian, L.; Chen, B.; Zhao, R.; Bednarz, M. S.; Kellar, K. A.; Mulheron, J. G.; Batorsky, R.; Roongta, U.; Kamath, A.; Marathe, P.; Ranadive, S. A.; Sack, J. S.; Tokarski, J. S,; Pavletich, N. P.; Lee, F. Y. F.; Webster, K. R.; Kimball, S.D. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolul]methyl]thiol]-2-thiazolyl-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. 2004, 47, 1719-1728.
24. Chen, Y. P.; Sharma, S. K.; Ramsey, T. M.; Jiang, L.; Martin, M. S.; Baker, K.; Adams, P.; Bair, K. W.; Kaelin, W. G. Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad Sci. USA. 1999, 96, 4325-4329.
25. Mendoza, N.; Fong, S.; Marsters, J.; Koeppen, H.; Schwall, R.; Wickramasinghe, D, Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res. 2003, 63, 1020-1024.
26. Krek, W.; Ewen, M. E.; Shirodkar, S.; Arany, Z.; Kaefin, W. G. Jr.; Livingston, D. M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 1994, 78, 161-172.
27. Dynlacht, B. D.; Flores, O.; Lees, J. A.; Harlow, E. Differential regulation of E2F transactivation by cyclin-cdk2 complexes. Genes Dev. 1994, 8, 1772-1786.
28. Xu, M.; Sheppard, K. A., Peng, C. Y.; Yee, A. S.; Piwinica-Worms, H. Cyclin A/Cdk2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. Cell. Biol. 1994, 14, 8420-8431.
29. Kitagawa, M.; Higashi, H.; Suzuki-Takahashi, I; Segawa, K.; Hanks, S. K.; Taya, Y.; Nishimura, S.; Okuyama, A. Phosphorylation of E2F-1 by Cyclin A-Cdk2. Oncogene 1995, 10, 229-236.
30. Matranga, C. B.; Shapiro, G. I. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res. 2002, 62, 1707-1717.
31. Ma, Y.; Cress, W. D.; Haura, E. B. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F-1 and repression of Mcl-1. Mol. Cancer Ther. 2003, 2, 73-81.
32. Jiang, J.; Matranga, C. B.; Cai, D.; Latham, V. M. Jr.; Zhang, X.; Lowell, A. M.; Martelli, F.; Shapiro, G. I. Flavopiridol-induced apoptosis during S-phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res. 2003, 63, 7410-7422.
33. Thomas, A.; Culshaw, J.; Byth, K.; Oakes, S. The discovery of 4-amino-2-anilino-5-cyanopyrimdines as selective CDK inhibitors and potential orally active anti-tumor agents. EORTC-NCI-AACR International Conference on "Molecular Targets and Cancer Therapeutics" Boston, MA, 2003, Poster, C63.
34. Thomas, A. P.; Barton, P. J.; Culshaw, J, D.; Fisher, E.; Heaton, D. W.; Newcombe, N. J.; Byth, K. F.; Oakes, S. E. The discovery of 4-alkoxy-2-anilino-5-cyanopyrimidines - SAR and characterization of potent and selective CDK inhibitors. 95th Annual Mtg. Proc. Am. Assoc. Cancer Res.: Orlando, FL, 2004, Abstr, 836.
35. Byth, K. F.; Wilkinson, R.; McGregor, S.; Geh, C.; Forder, C.; Oakes, S.; Walker, M.; Newcombe, N.; Thomas, A.; Barker, A. Development of selective cyclin-dependent kinase inhibitors: pharmacodynamic characterization in human tumour xenografts. 95th Annual Mtg. Proc. Am. Assoc. Cancer Res.: Orlando, FL, 2004, Abstr, 832.
36. Byth, K. F.; Cooper, N.; Culshaw, J. D.; Heaton, D. W.; Oakes, S. E.; Minshull, C. A.; Norman, R. A.; Pauptit, R. A.; Tucker, J. A.; Breed, J.; Pannifer, A.; Rowsell, S.; Stanway, J. J.; Valentine, A. L.; Thomas, A. P. Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 2249-2252.
37. Byth, K. F.; Culshaw, J. D.; Green, S.; Oakes, S. E.; Thomas, A. P. Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 2245-2248.
38. Bergnes, G.; Ha, E.; Feng, B.; Smith, W. W.; Yao, B.; Tochimoto, T.; Lewis, E. R.; Lee, Y.; Moody, R. S.; Finer, J. T.; Turincio, R. A.; Wood, K. W.; Sakowicz, R.; Crompton, A. M. Chabala, J. C.; Morgans, D. J. Jr.; Sigal, N. H.; Sabry, J. H. Mitotic kinesin-targeted antitumor agents: Discovery, lead optimization and antitumor activity of a series of novel quinazolinones as inhibitors of kinesin spindle protein (KSP). 223rd Am. Chem. Soc. Natl. Mtg. Orlando, FL, 2002.
39. Misra, R. N.; Xiao, H.; Williams, D. K.; Kim, K. S.; Lu, S.; Keller, K. A.; Mulheron, J. G.; Batorsky, R.; Tokarski, J. S.; Sack, J. S.; Kimball, S. D.; Lee, F. Y.; Webster, K. R. Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem. Lett. 2004, 14, 2973-2977.
40. Sausville, E.A. Cyclin-dependent kinase modulators studied at the NCL: Pre-clinical and clinical studies. Curr. Med. Chem. Anti-Cancer Agents 2003, 3, 47-56.
41. Kelland, L.R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status. Expert Opin. Investig. Drugs 2000, 9, 2903-11.
42. Zhai, S.; Senderowicz, A. M.; Sausville, E. A.; Figgs, W. D. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Pharmacother. 2002, 36, 905-911.
43. Tan, A.R., Swain, S.M. Review of flavopiridol, acyclin-dependent kinase inhibitor, as breast cancer therapy. Semin Oncol 2002, 29, 77-85.
44. Burdette-Radoux, S.; Tozer, R. G.; Lohmann, R.; Quirt, I; Ernst, D. S.; Walsh, W.; Wainman, N.; Colevas, D.; Eisenhauer, E. NCIC CTC phase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma (IND.137). 38th Ann. Mtg. Am. Soc. Clin. Oncol. : Orlando, FL, 2002, Abst 1382.
45. Tan, A. R.; Headlee, D.; Messmann, R.; Sausville, E. A.; Arbuck, S. G.; Murgo, A. J.; Melillo, G.; Zhai, S.; Figg, W. D.; Swain, S. M.; Senderowicz, A. M. Phase I clinical and pharmacokinetics study of flavopiridol administered as a daily 1 hour infusion in patients with advanced neoplasms. J Clin Oncol 2002, 20: 4074-4082.
46. Letrent, S.; Callegari, F.; Wong, R.; Burris, H.; Cohen, R.; Lorusso, P.; Papadimitrakopoulou, V.; Shapiro, T.; Griffin, T., Decillis, A. Evaluation of a novel RNA biomarker of CDK2 inhibition in phase 1 clinical trials with BMS-387032. 40th Ann. Mtg. Am. Soc. Clin. Oncol. New Orleans, LO, 2004, Abstr. 2031.
47. Ciomei, M.; Albanese, C.; Rossi, R.; Pastori, W.; Marsiglio, A.; Ciavolella, A.; Roletto, F.; Vulpetti, A.; Pevarello, P. The CDK2/cyclin A inhibitor PUN-252808 blocks cell cycle progression and induces apoptosis in tumor cells both in vitro and in vivo. 92th Annual Mtg. Proc. Am. Assoc. Cancer Res.: New Orleans, LO, 2001, Abstr, 2179.
48. Pevarello, P.; Amici, R.; Villa, M., Salom, B.; Vulpetti, A.; Varasi, M.; Brasca, M. G.; Traquandi, G.; Nesi, M. Phenylacetamidothiazole derivatives, process for their preparation and their use as antitumor agents. PCT Pat. Apl. WO 0308365, July 2, 2002
49. Cai, D.; Byth, K.; Shapiro, G. I. A novel CDK inhibitor induces cell cycle blockade, E2F-1 dependent apoptosis and cytotoxic synergy with DNA-damaging agents. 95th Annual Mtg. Proc. Am. Assoc. Cancer Res.: Orlando, FL, 2004, Abstr, 826.
50. Reich, S. H.; Wallace, M. B. Pyrazoles for inhibiting protein kinase. PCT Pat. Apl. WO 0179198, Apr. 5, 2001.
51. Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K., Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C., Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M. C.; Miller, K. M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nature Med. 2004, 10, 262-267.
52. Tang, J.; Shewchuk, L. M.; Sato, H.; Hasegawa, M.; Washio, Y., Nishigaki, N. Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and x-ray crystallographic analysis. Bioorg. Med. Chem. Lett. 2003, 13, 2985-2988.
53. Pevarello, P.; Brasca, M. G.; Amici, R.; Orsini, P.; Traquandi, G.; Corti, L.; Piutti, C.; Sansonna, P.; Villa, M.; Pierce, B. S.; Pulici, M.; Giordano, P.; Martina, K.; Fritzen, E. L.; Nugent, R. A.; Casale, E.; Cameron, A.; Ciomei, M.; Roletto, F.; Isacchi, A.; Fogliatto, G.; Pesenti, E.; Pastori, W.; Marsiglio, A.; Leach, K. L.; Clare, P. M.; Fiorentini, F.; Varasi, M.; Vulpetti, A.; Warpehoski, M. A. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J. Med Chem. 2004, 47, 3367-3380.
54. Mercurio, C.; Pastori, W.; Crippa, S.; Alzani, R.; Albanese, C.; Muzio, M.; Croci, V.; Maarsiglio, A.; Ciomei, M.; Roletto, F.; Braasca, G.; Pevarello, P.; Bischoff, J. R. In vitro and in vivo characterization of the CDK2 inhibitor PHA-533533. 95th Annual Mtg. Proc. Am. Assoc. Cancer Res.: Orlando, FL, 2004, Abstr, 824.
55. Pevarelo, P.; Brasca, G.; Nesi, M.; Orsini, P.; Traquandi, G.; Vulpetti, A.; Casale, E.; Fiorentini, F.; Ciomei, M.; Roletto, F.; Warpehoski, M. 3-aminopyrazole Cdk-2 inhibitors: Discovery and optimization as anti-tumor agents. 94th Annual Mtg. Proc. Am. Assoc. Cancer Res.: Washington, DC, 2003, Abstr, 3975.
56. Pevarello P., Brasca M G., Vulpetti A., Ciomei M., Roletto F., Warpehoski M. Discovery and optimization of CDK-2 inhibitors as anti-tumor agents. 1st Anglo-Swedish Medicinal Chemistry Symposium, Are, Siveden, 2003, Lecture, 2.
57. Alzani, R.; Torre, D. P.; Albanese, C.; Terron, A.; Caprera, F.; Bassignani L.; Ciomei, M, Ex vivo analysis to study the mode of action of a CDK2 inhibitor. 93th Annual Mtg. Proc. Am. Assoc. Cancer Res.: San Francisco, CA, 2002, Abstr, 329.
58. Pevarello, P.; Fancelli, D.; Vulpetti, A.; Amici, R.; Villa, M.; Pittala, V.; Ciomei, M.; Mercurio, C.; Varasi, M.; Brasca, G. B. 3-Amino-pyrrolo[3,4-c]pyrazoles: A new class of CDK2 inhibitors. 95th Annual Mtg. Proc, Am. Assoc. Cancer Res.: Orlando, FL, 2004, Abst, 2479.
59. Yue, E. W.; DiMeo, S. V.; Higley, C. A.; Markwalkder, J. A.; Burton, C. R.; Benfield, P. A.; Grafstrom, R. H.; Cox, S.; Muckelbauer, J. K.; Smallwood, A. M.; Chen, H.; Chang, C-H.; Trainor, G. L.; Seitz, S. P. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: heterocycles at C3. Bioorg. Med. Chem. Lett. 2004, 14, 343-46.
60. Emanuel, S. L.; Rugg, C.; Lin, R.; Connolly, P.; Napier, C.; Hollister, B.; Hall, C.; Middleton, S. A. Evaluation of the CDK inhibitor JNJ-7706621 as a targeted antitumor agent. 95th Annual Mtg. Proc. Am. Assoc. Cancer Res.: Orlando, FL, 2004, Abstr, 833.
61. Luk, K-C.; Simcox, M. E.: Schutt, A.; Rowan, K.; Thompson, T.; Chen, Y.; Kammlott, U.; DePinto, W.; Dunten, P,; Dermatakis, A. A new series of Potent oxindole inhibitors of CDK2. Bioorg. Med. Chem. Lett. 2004, 14, 913-17.
62. Dermatakis A; Luk K C; DePinto W. Synthesis of Potent oxindole CDK2 inhibitors. Bioorg. Med. Chem. 2003, 11, 1873-1881.
63. Ortega, S.; Malumbres, M.; Barbacid, M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 2002 1602, 73-87.
64. Shapiro,G.I.; Harper,J.W. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Inves. 1999, 104, 1645-1653.
65. Steiner, M. S.; Zhang, Y.; Farooq, F.; Lerner, J.; Wang, Y.; Lu, Y. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Therapy 2000, 7, 360-372.
66. Som, R.; O'Reilly, T.; Furet, P., Muller, L.; Stephan, C.; Zumstein-Mecker, S.; Frets, H.; Fabbro, D.; Chaudhuri, B. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl. Cancer Inst. 2001, 93 436-446.
67. Fry, D. W.; Bedford, D. C.; Harvey, P. H; Fritsch, A.; Keller, P, R. Wu, Z.; Dobrusin, E.; Leopold, W. R. Fattaey, A,; Garrett, M. D. Cell cycle and biochemical effects of PD 0183812. J. Biol. Chem. 2001, 276, 16617-16623.
68. Fry, D. W.; Harvey, P. J.; Keller, P. R.; Elliott, W. L.; Meade, M.; Trahet, E.; Albassam, M.; Zheng, X.; Leopold, W. R.; Pryer, N. K.; Toogood, P. L. Specific inhibition of Cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3, 1427-1437.
69. Barvian, M.; Boschelli, D.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey, P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 2000, 43, 4606-4616.
70. Nugiel, D.A.; Vidwans, A.; Etzkorn, A.M.; Rossi, K.A.; Benfield, P.A.; Burton, C. R., Cox, S.; Doleniak, D.; Seitz, S.P. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern. J. Med. Chem. 2002, 45, 5224-5232.
71. Carini, D. J.; Kaltenbach, R. F.; Liu, J.; Benfield, P. A.; Boylan, J.; Boisclair, M.; Brizuela, L.; Burton, C. R.; Cox, S.; Grafstrom, R.; Harrison, B. A.; Harrison, K.; Akamike, E.; Markwalder, J. A.; Nakano, Y.; Seitz, S. P.; Sharp, D. M.; Trainor, G. L.; Sielecki, T. M. Identification of selective inhibitors of cyclin dependent kinase 4. Bioorg. Med. Chem. Lett. 2001, 11, 2209-2211.
72. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida,T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, L; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H.. Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design. J. Med. Chem. 2001, 44, 4615-4627.
73. Honma, T.; Yoshizumi, T.; Hashimoto, N.; Hayashi, K.; Kawanishi, N.; Fukasawa, K.; Takaki, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S.; Morishima, H. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem. 2001, 44, 4628-4640.
74. Kubo A.; Nakagawa K.; Varma R. K.; Conrad N. K.; Cheng J. Q.; Lee W. C.; Testa J. R.; Johnson B. E.; Kaye F. J.; Kelley M. J. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin. Cancer Res. 1999, 5 4279-4286.
75. McInnes, C.; Wang, C.; Anderson, S.; O'Boyle, J.; Jackson, W.; Kontopidis, G.; Meades, C.; Mezna, M.; Thomas, M.; Wood, G.; Lane, D. P.; Fischer, P. M. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem. Biol. 2004, 11, 525-534.
76. Dobrusin, E. M.; Hamby, J. M.; Kramer, J. B.; Schroeder, M. C.; Showalter, H. D. H.; Toogood, P.; Trumpp-Kallmeyer, S. A. Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation. PCT Pat. Apl. WO 9961444, May 10, 1999.
77. Barvian, M. R.; Bathini, Y.; Dobrusin, E. M.; Kaltenbronn, J. S., Micetich, R. G.; Sidhu, I. S.; Singh, R.; Toogood, P. L.; Winters, R. T. Quinqzolines and their use for inhibiting cyclin-dependent kinase enzymes. PCT Pat. Apl. WO 0138315, Nov. 3, 2000.
78. Booth, R. J.; Dobrusin, E. M.; Josyula, V. P.; Venkata, N.: McNamara, D. J.; Toogood, P. L.. Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors. PCT Pat. Apl. WO 0155147, Jan. 23, 2001.
79. Denny, W. A.; Dobrusin, E. M.; Kramer, J. B.; McNamara, D. J.; Rewcastle, G. W.; Showalter, H. D. H.; Toogood, P. L.. Pteridinones as kinase inhibitors. PCT Pat. Apl. WO 0119825, June 21, 2000.
80. Booth, R. J.; Dobrusin, E. M.; Toogood, P. L.; Vanderwel, S. N. 5-alkylpyridol[2,3-d]pyrimidines tyrosine kinase inhibitors. PCT Pat. Apl. WO 0170741, Jan. 29, 2001.
81. Repine, J. T. 2-thia-1,6,8-triaza-naphthaletic-2,2-dioxides as cdk inhibitors. PCT Pat. Apl. WO 0362246, Jan. 13, 2003.
82. Barvian, M. R.; Booth, R. J.: Quin, J. III.; Repine, J. T.; Sheehan, D. J.; Toogood, P. L.; Vanderwel, S. N.; Zhou, H. 2-(pyridine-2-ylamino)-pyido[2,3d]pyrimidin-7-ones. PCT Pat. Apl. WO 0362236, Jan.10, 2003.
83. Breault, G. A.; Ellston, R. P. A.; Green, S.: James. S. R.; Jewsbury, P. J.; Midgley, C. J.; Pauptit, R. A.; Minshull, C. A.; Tucker, J. A., Pease, J. E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimization of substituted 2,4-bis anilino pyrimidines. Bioorg. Med. Chem. Lett. 2003, 13, 2961-2966.
84. Beattie, J. F.; Breault, G. A.; Ellston, R. P. A.; Green, S.; Jewsbury, P. J.; Midgley, C. J.; Naven, R. T.; Minshull, C. A.; Pauptit, R. A.; Tucker, J. A.; Pease, J. E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimization or substituted 4,6-Bis anilino pyrimidines. Bioorg. Med Chem. Lett. 2003, 13, 2955-2960.
85. Ikuta, M.; Kamata, K.; Fukasawa, K.; Honma, T.; Machida, T. Hirai, H.; Suzuki-Takahashi, I.; Hayama, T. & Nishimura, S. Crystallographic approach to identification of cyclin-dependent 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem. 2001, 276, 27548-27554.
86. Hayama, T.; Hayashi, K.; Honma, M.; Takahashi, I. Biarylurea derivatives. PCT Pat. Apl. WO 0107411, July 26, 2000.
87. Chen, L.; Ding, Q.; Gillespie, P.; Kim, K.; Lovey, A. J.; McComas, W. W.; Mullin, J. G. Jr.; Perrotta, A. Diaminothiazoles. PCT Pat. Apl. WO 02057261, Jan. 18, 2001.
88. Chu, X.; Ding, Q.; Jiang, N.; Kim, K.; Lovey, A. J.; McComas, W. W.; Mullin, J. G. Jr.; Tilley, J. W. Diaminothiazoles. PCT Pat. Apl. WO2003097048 A1, May 12, 2003.
89. Chong, W. K. M.; Chu, S. S.; Duvadie, R. R.; Li, L.; Xiao, W.; Yang, Y. 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases. PCT Pat. Apl. WO 9921845, Oct. 27, 1998.
90. Sanhez-Martinez, C.; Shih, C.; Zhu, G.; Li, T.; Brooks, H. B.; Patel, B. K. R.; Schultz, R. M.; DeHahn, T. B.; Spencer, C. D.; Watkins, S. A.; Ogg, C. A.; Considine, E.; Dempsey, J. A.; Zhang, F. Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo-3,4-carbazoles versus bis-indolylmaleimides. Bioorg. Med. Chem. Lett. 2003, 13, 3841-3846.
91. Dickerson, S. H., Drewry, D. H. Oxindole derivatives. PCT Pat. Apl. WO 0220524, June 28, 2001.
92. Eberwein, D. J.; Harrington, L.; Griffin, R.; Tadepalli, S.; Knick, V.; Phillips, K.; Dickerson, S.; Davis, S. Biological evaluation of GW491619, a novel substituted oxindole CDK4 ser/thr inhibitor. 93th Annual Mtg. Proc. Am. Assoc. Cancer Res.: San Francisco, CA, 2002 Abstr, 1611.
93. Rane, S.G.; Dubus, P.; Mettus, R.V.; Galbreath, E.J.; Boden, G.; Reddy, E.R; Barbacid, M. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat. Genet. 1999, 22, 44-52.
94. Tsutsui, T.; Hesabi, B.; Moons, D.S.; Pandolfi, P.P.; Hansel, K.S.; Koff, A.; Kiyokawa, H. Targeted disruption of Cdk4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol. Cell. Biol. 1999. 19, 7011-7019.
95. Ortega, S.; Prieto, I.; Odajima, J.; Martin, A.; Dubus, P.; Sotillo, R.; Barbero, J.L.; Malumbres, M.; Barbacid, M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 2003, 35, 25-31.
96. Tetsu, O.; McCormick, F. Proliferation of cancer cells despite Cdk2 inhibition. Cancer Cell 2003, 3, 233-245.
97. McCormick, J.; Gadgeel, S.M.; Helmke, W.; Chaplen, R.; Van Leeuwen, B.; Mauro D.; Youssoufian, H.; Decillis, A.; Bai, S.; Lorusso, P.M. Phase I study of BMS-387032, a cyclin dependent kinase (CDK) 2 inhibitor. 39th Ann. Mtg. Am. Soc. Clin. Oncol.: Chicago, IL, 2003, Abstr. 835.
98. Jones, S. F.; Burris, H. A.; Kies, M.; Willcutt, N.; Degen, P.; Bai, S.; Mauro D.; Decillis, A.; Youssoufian, H.; Papadimitrakopoulou, V. Phase I study to deretmine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. 39th Mtg. Proc. Am. Soc. Clin. Oncol. : Chicago, IL, 2003, Abstr. 798.
99. Shapiro, G.; Lewis, N.; Bai, S.; Van Leeuwen, B.; Mauro D.; Youssoufian, H.; Decillis, A.; Cohen, R.B. Helmke, W.; Chaplen, R.; Van Leeuwen, B.; Lorusso, P.M. Phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 with 24-hr infusion given every three weeks in patients with metastatic refractory solid tumors. 39th Mtg. Proc. Am. Soc. Clin. Oncol.: Chicago, IL, 2003, Abstr. 799.
100. INK4a, gene expression radiosensitizes non-small cell lung carcinoma cells in a p53 dependent manner. Oncogene, 2000, 19, 5359-5366.
101. Plath, T.; Peters, M.; Detjen, K.; Welzel, M.; von Marschall, Z.; Radke, C.; Wiedenmann, B.; Rosewicz, S. Overexpression of pRb in human pancreatic carcinoma cells: Function in chemotherapy-induced apoptosis. J. Natl. Cancer Inst. 2002, 94, 129-141.
102. INK4a expression enhances CPT-11 induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells. Int. J. Cancer 2000, 86 197-203.
103. INK4a, contributes to the outcome of cancer therapy. Cell 2002, 109, 335-346.
104. Davis, S. T; Benson, B. G.; Bramson, H. N.; Chapman, D. E.; Dickerson, S. H. ; Dold, K. M. ; Eberwein, D. J.; Edelstein, M., Frye, S. V.; Gampe, R. T. Jr.; Griffin, R. J.; Harris, P. A.; Hassel. A. M.; Holmes, W. D.; Hunter, R. N.; Knick, V. B.; Lackey, K.; Lovejoy, B.; Luzzion, M. J.; Murray, D.; Parker, P.; Rocque, W. J.: Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Prevention of chemotherapy-induced alopecia in rats by Cdk inhibitors. Science 2001, 291, 134-137.